Compare GSK plc (GSK) vs iShares 20 Plus Year Treasury Bond ETF (TLT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs iShares 20 Plus Year Treasury Bond ETF — how do they compare? GSK plc trades at $46.5 (market cap $91.88B), while iShares 20 Plus Year Treasury Bond ETF trades at $77.98 (market cap $47.61B). The key difference: GSK plc is the larger of the two by market cap, and GSK plc pays a 3.9% dividend while iShares 20 Plus Year Treasury Bond ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and iShares 20 Plus Year Treasury Bond ETF for 83 Days on average.
| GSK | TLT | |
|---|---|---|
Market Cap | $91.88B | $47.61B |
Volume | 7,730,529 | 49,263,490 |
Sector | Health | Fixed Income |
52-Week High | $61.18 | $92.06 |
52-Week Low | $43.24 | $77.11 |
Typical Hold Time | 93 Days | 83 Days |
Enterprise Value | $111.88B | — |
Dividend Yield | 3.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $46.54, down 1.02% with bearish technical signals but strong fundamentals including 29.73% ROE and consistent earnings beats. The company maintains robust profitability with 72.73% gross margins and is actively expanding its oncology pipeline through strategic partnerships. Recent developments include a $750M cancer therapy acquisition and advancing mRNA vaccine candidates.
GSK presents a mixed outlook with strong operational performance offset by technical weakness. Investment appeal lies in valuation multiples below industry averages and pipeline expansion, though risks include HIV patent expirations and manufacturing restructuring. Analyst consensus leans cautious with 55% hold ratings amid near-term headwinds.
TLT, the iShares 20+ Year Treasury Bond ETF, trades at $77.87, up 0.94% on the day but remains in a prolonged downtrend, down 11% year-to-date and 46% over five years. The technical picture is bearish with moving averages signaling continued pressure, while oscillators show neutral momentum. Recent news highlights a challenging bond market environment with Treasury yields reaching multi-decade highs, creating headwinds for long-duration bond funds.
The outlook for TLT remains heavily dependent on interest rate direction, with current high yields offering potential income but significant price risk if rates continue rising. Key investment considerations include duration risk exposure, inflation expectations, and Federal Reserve policy shifts. The fund's dividend payments provide income, but capital preservation remains challenging in the current rising rate environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About iShares 20 Plus Year Treasury Bond ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index, and it will invest at least 90% of its assets in US Treasury securities that the advisor believes will help the fund track the underlying index. The underlying index measures the performance of public obligations of the US Treasury that have a remaining maturity greater than or equal to twenty years.
Read more on TLT →
